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Abstract
Introduction Carotid artery stenting (CAS) requires adequate
follow-up imaging to assess complications such as in-stent
stenosis or occlusion. Options include digital subtraction
angiography, CTangiography, ultrasound, and MR angiogra-
phy (MRA), which may offer a non-invasive option for CAS
follow-up imaging. The aim of this study was to assess
contrast-enhanced MRA (CE-MRA) and three-dimensional
time-of-flightMRA (3D-TOF) for visualization of the in-stent
lumen in different carotid stents.
Methods In this study, we compared CE-MRA and 3D-
TOF of five different carotid stents (Guidant Acculink®,
Cordis Precise®, Boston Wallstent®, Abbot Vascular
Xact®, Cook Zilver®) in three diameters (4, 6, and 8 mm)
using a vascular flow model at 3.0 T with the help of a
recently developed carotid surface coil. Stent-related arti-
facts were objectively assessed by calculating artificial
lumen narrowing (ALN) and relative in-stent signal (RIS).
Results RIS and ALN depended heavily on stent type, stent
diameter, and the employed MR sequence. ALN and RIS
were relatively favorable for Acculink®, Precise®, and
Zilver® stents with both CE-MRA and 3D-TOF. CE-MRA
provided better results for the Wallstent, while the Xact
stent was difficult to visualize with both MRA protocols.
Conclusion Both CE-MRA and 3D-TOF are viable options
for depicting the in-stent lumen in carotid stents. For specific
stents, 3D-TOF provided image quality comparable to CE-
MRA and may thus be suitable for in vivo assessment.
Development of stent-specific pathways for follow-up imag-
ing seems advisable to address stent-related differences in
image quality.
Keywords Three-dimensional time-of-flight angiography.
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Contrast-enhanced MR angiography
Abbreviation Key
CAS Carotid artery stenting
CE-MRA Contrast-enhanced magnetic resonance
angiography
CTA Computed tomography angiography
3D-TOF Three-dimensional time-of-flight angiography
ALN Artificial lumen narrowing
RIS Relative in-stent signal
MRA Magnetic resonance angiography
DSA Digital subtraction angiography
SI Signal intensity
D Diameter
Introduction
Carotid artery stenting (CAS) is a widely used method for
prevention of stroke in individuals with symptomatic or high-
grade carotidarterystenosis. Toassesstreatment effectiveness
and reliably detect possible complications such as restenosis
orvesselocclusion,adequatefollow-upis mandatory.Options
include Doppler ultrasound, digital subtraction angiography
(DSA), CT angiography (CTA), and magnetic resonance
angiography (MRA). While DSA and CTA require the use of
ionizingradiation,ultrasoundisuser-dependantandmayoffer
limited reproducibility. In comparison, MRA offers the
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radiation,makingitapromisingoptionforfollow-upimaging.
Stent-related artifacts,however, currently limitits wide-spread
diagnostic use. Previous studies on MRA in the presence of
vascular stents focused on contrast-enhanced MRA (CE-
MRA). For CE-MRA, it has been shown that the in-stent
lumen can be visualized at different field strengths [1–9].
However, stent-related artifacts leading to artificial lumen
narrowing (ALN) and in-stent signal attenuation limit lumen
visibility. Furthermore, CE-MRA requires the use of gado-
linium contrast agents, which carry the risk of allergic
reactions and renal complications, including nephrogenic
systemic fibrosis [10, 11] in patients with coexisting renal
disease. Time-of-flight angiography (TOF) is a well-
established and widely used sequence type for depicting
intra- and extracranial vascular structures that do not require
the use of contrast agents. To date, no clear guidelines exist
for follow-up examinations after CAS [12]. To help develop
standard protocols for follow-up imaging, different modali-
ties need to be objectively compared regarding ALN, in-stent
signal attenuation, and stent-related artifacts. Previous studies
on stent imaging employed CE-MRA, CT angiography, and
DSA [1–9]. To our knowledge, no investigations exist to
date that systematically analyze lumen visibility and stent-
related artifacts with three-dimensional TOF angiography
(3D-TOF). With high-field MRI and surface coils, powerful
tools have been developed to shorten acquisition time and
improve image quality. This may help overcome weaknesses
traditionally associated with TOF angiography, making it a
promising sequence type for stent imaging. The purpose of
this study was to assess the effectiveness and reliability of
3D-TOF in depicting the intra-stent lumen and to evaluate its
potential use in follow-up imaging after CAS, focusing
especially on differences to CE-MRA.
Materials and methods
Vascular phantom
A vascular phantom was constructed using a hollow plastic
cylinder filled with ultrasound gel (LIBOmed, Kleve,
Germany). Silicon tubes (neoLab GmbH, Heidelberg,
Germany) were used as vessels. Stents were placed inside
the tubes, and the system was filled with normal saline
solution. For CE-MRA, contrast medium was added at a
dilution of 1:200 (Gadovist, Bayer Schering Pharma AG,
Berlin, Germany). Flow was achieved by connecting a
cardiovascular pump (3M Delphin II centrifugal pump, 3M,
St. Paul, MN, USA). Flow was pulsatile, with flow volume
set to 400 ml/min, approximating in vivo conditions for the
common carotid artery [13]. Five different stent types
(Guidant Acculink®, Cordis Precise®, Boston Wallstent®,
Abbot Vascular Xact®, and Cook Zilver®) were deployed
in tubes with diameters of 4, 6, and 8 mm. Table 1 gives an
overview of the stents used in this study.
MR imaging
All MR images were obtained on a Siemens Trio 3.0-T
scanner (Siemens Medical Solutions, Erlangen, Germany).
A carotid surface coil (Machnet B.V., Eelde, The Nether-
lands) was used for all sequences in this study. The coil was
attached to the plastic cylinder, which functioned as a neck
phantom containing the silicone vessels. The vascular flow
phantom was placed inside the MR scanner with the
longitudinal axis of the stented vessel segment roughly
parallel to B0. Sequence parameters for 3D-TOF and CE-
MRA are summarized in Table 2. To illustrate stent
geometry (Fig. 1), dynamic flat-panel detector images were
obtained (Siemens Axiom Artis Flat Panel, Siemens
Medical Solutions, Erlangen, Germany).
Image analysis
Image analysis was performed using the free medical
imaging software Osiris (http://www.dim.hcuge.ch/osiris/
01_Osiris_Presentation_EN.htm). Coronal multiplanar
reformations were used for both 3D-TOF and CE-MRA.
In-stent signal attenuation was assessed by calculating the
relative in-stent signal (RIS) inside the stent. This was
achieved by obtaining mean values of signal intensity (SI)
from six regions of interest (ROI) placed in the visible
tube lumen inside (at least 2 mm away from the stent wall)
and outside the stent (SIin-stent and SItube, respectively).
ROIs were placed manually and centered on the stent axis.
For all measurements, ROIs were placed at least 1 cm
away from the stent ends because of strong artifacts
occurring in the distal stent regions. The RIS was
calculated accordingly:
RIS % ðÞ ¼SIin stent=SItube ðÞ   100%:
The mean and standard deviation were obtained for the
resulting three RIS values for each stent and a paired
Student’s t test was used to compare differences between
CE-MRA and 3D-TOF for the RIS values of all sizes of
each stent. The level of statistical significance was set at
0.01.
Visible lumen diameter and ALN were determined in a
manner similar to previous investigations [5]: For objective
evaluation, signal intensity profiles were obtained along the
x-axis (perpendicular to the stent axis) both inside the mid-
segment of the stent and outside the stent. The mean of the
SI values of first 10 pixels along this profile (outside the
stent) was defined as the SI of the background gel (SIgel). In
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with more than twice the SI of SIgel. The number of “lumen
pixels” along the profiles inside and outside the stent
represents the in-stent lumen diameter (Din-stent) and tube
lumen diameter (Dtube), respectively. Artificial lumen
narrowing was then expressed as
ALN % ðÞ ¼Dtube   Din stent ðÞ =Dtube   100%:
A higher ALN value therefore correlates with a smaller
apparent lumen diameter on the images and thus with worse
lumen visibility. Given the pixel-by-pixel analysis, no mean
or standard deviations were obtained for ALN values. This
method of ALN calculation was chosen to adequately
compare stent appearance under experimental conditions,
with the assumption that differences in-stent strut thickness
were negligible.
Results
In-stent signal attenuation
The RIS differed markedly between stent and sequence
types as well as stent diameters (Fig. 2, Table 3). The RIS
for the Wallstent® was markedly higher for CE-MRA than
for 3D-TOF (44% vs. 9% on average for all sizes, p<0.001
for each size). In comparison, the average differences for
the Acculink® (79% for CE-MRA vs. 79% for 3D-TOF for
all sizes), Precise (40% vs. 44%), and Zilver® stents (85%
vs. 77%) were not significant. Finally, the Xact® stent
showed very low intraluminal signal with both sequences
(RIS <11% for CE-MRA, <4% for 3D-TOF) and as a result
had poor lumen visibility. With the exception of the 6 mm
Zilver® and 6 mm Acculink®, all stents showed higher RIS
values with larger stent diameters.
Artificial lumen narrowing
For the Acculink®, Precise®, and Zilver® stents, ALN was
relatively low (<25%) and roughly comparable for CE-MRA
and3D-TOFsequences(Fig.3). The mean ALN for this group
of stents was 17.6% with CE-MRA and 25.3% with 3D-TOF
(average for all stent sizes), although marked variations
occurred between stent types and sizes. The Wallstent®
showed similarly low ALN values (<30%) only for the 6-
and 8-mm diameters with CE-MRA. The 4-mm stent and all
3D-TOF acquisitions had ALN values >60%, consistent with
poor lumen visibility. Finally, the Xact® stent showed an
almost complete in-stent signal void, and ALN was close to
100% on average for both CE-MRA, and 3D-TOF.
Table 1 Overview of stents included in this study
Stent name Name used in
figures/tables
Stent diameter/
length (mm)
Tube
diameter
(mm)
Stent
design
Material Manufacturer
Zilver® Zil8 9/40 8 Open cell Nitinol Cook Vascular Incorporated,
Vandergrift, PA, USA Zil6 7/40 6
Zil4 5/40 4
Acculink® Acc8 9/30 8 Open cell Nitinol Guidant, part of Boston Scientific
Corporate, Natick, MA, USA Acc6 7/30 6
Acc4 5/30 4
Precise® Pre8 9/30 8 Open cell Nitinol Cordis Corporation, Bridgewater,
NJ, USA Pre6 7/30 6
Pre4 5/30 4
Carotid Wallstent® Wal8 10/24 8 Closed cell Cobalt alloy Boston Scientific Corporate,
Natick, MA, USA Wal6 8/29 6
Wal4 6/22 4
Xact® Xac8 9/30 8 Closed cell Nitinol Abbot Vascular, Redwood City,
CA, USA Xac6 7/30 6
Table 2 Overview of sequence parameters
3D-TOF CE-MRA
TR (ms) 27 5.26
TE (ms) 2.98 1.57
Flip angle 35° 35°
Matrix size 256 256
Field of view 200 200
Slice thickness (mm) 0.8 0.8
Bandwidth (pixel) 400 320
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Artifact types
Appearance of stents with 3D-TOF and CE-MRA is shown
in Fig. 1 for the 8-mm stents. Two major types of stent-
related artifacts are described in the literature: susceptibility
artifacts and radiofrequency artifacts [6–8]. Susceptibility
artifacts are caused by the different magnetic susceptibility
of the stent material and the tissue around the stent.
Radiofrequency artifacts, on the other hand, result from
so-called eddy currents induced inside the stent struts,
shielding out the radiofrequency pulse and thus diminishing
signal strength. In this study, overall artifact patterns were
comparable between the two sequence types used, although
there were differences in the degree of observed artifacts.
The three artifact patterns most commonly observed in this
study were a strong signal gain or loss at the stent ends, a
signal void surrounding the stent struts and a homogenous
reduction of the in-stent-signal. Previous investigators have
pointed out that the strong artifacts encountered with
stainless steel-based stents may be related to susceptibility
artifacts, whereas the differences in artifacts for cobalt alloy
and nitinol-based stents may primarily be based on different
degrees of radiofrequency shielding [4, 14].
The degree of artifacts and subsequent changes in lumen
visibility, ALN, and RIS varied markedly depending on stent
type, size, and sequences used. Interestingly, although RIS
was generally higher for larger stent diameters (with few
exceptions), there was no likewise correlation for ALN,
although it was observed by other authors [15]. This may in
part be due to the different ways ALN and RIS were
obtained: RIS calculation included data from the homoge-
nous signal at least 2 mm away from the stent struts, whereas
the ALN was calculated from the SI profile across the entire
stent diameter, including the more inhomogeneous regions
Fig. 1 Stent appearance. Images
were obtained from Zil8, Acc8,
Pre8, Wal8,a n dXac8 stents.
DYNA represents a volumetric
coronal reconstruction from a
dynamic flat-panel detector CT
acquisition of the stents. 3D-TOF
indicates coronal images from
the three-dimensional time-of-
flight angiography study, and
CE-MRA represents coronal
images of contrast-enhanced
magnetic resonance angiography
performed for the respective
stents
Fig. 2 Relative in-stent signal.
Bars represent RIS values for
CE-MRA (dark gray bars) and
3D-TOF (light gray bars) for
each stent in the study. Standard
deviation is indicated by thin
bars
362 Neuroradiology (2011) 53:359–365near the actual stent. For some stent sizes, ALN was 0%,
which may be related to the limited spatial resolution along
the SI profile, not allowing detection of subtle changes in
apparent lumen diameter.
The Acculink® and Zilver® stents are open-cell, nitinol-
based stents. Despite the presence of stent-related artifacts,
these stents all showed relatively good lumen visibility with
both sequence types, correlating with low ALN (<25%) and
relatively high RIS (>75%) values which were comparable
for both CE-MRA and 3D-TOF (Figs. 2 and 3). These
results indicate that 3D-TOF may be a feasible alternative
to CE-MRA in imaging these stents, and in vivo studies of
the 3D-TOF sequence may further elucidate its clinical
usefulness in follow-up imaging in patients with these
stents. In addition, 3D-TOF may be particularly useful in
situations where use of gadolinium contrast agents may be
harmful or impossible, e.g., in patients with renal insuffi-
ciency to avoid the development of complications such as
nephrogenic systemic fibrosis. Another open-cell, nitinol-
based stent in this study, the Precise®, showed considerable
loss of in-stent signal (RIS <45% with both sequences) and
moderate lumen narrowing (ALN <30%). Although these
values are worse than for the Zilver® and Acculink® stents,
the results were comparable for both 3D-TOF and CE-
Table 3 Detailed results for relative in-stent signal (RIS) and artificial lumen narrowing (ALN)
Average RIS (%)
for CE-MRA
Average RIS (%)
for 3D-TOF
p value (RIS CE-MRA
vs. 3D-TOF)
ALN (%) for
CE-MRA
ALN (%) for
3D-TOF
Wal8 60.0 13.2 0.0006 25.0 60.0
Wal6 54.1 9.1 0.0005 30.0 100.0
Wal4 16.3 4.7 0.0003 75.0 100.0
Wallstent® average 43.5 9.0 43.3 86.7
Zil8 100.8 98.7 0.3154 8.3 30.0
Zil6 85.4 59.7 0.0158 20.0 25.0
Zil4 69.4 71.1 0.3763 37.5 20.0
Zilver® average 85.2 76.5 21.9 25.0
Acc8 80.8 91.5 0.0508 0.0 20.0
Acc6 89.6 73.4 0.0439 0.0 25.0
Acc4 67.0 72.7 0.2691 25.0 20.0
Acculink® average 79.2 79.2 8.3 21.7
Pre8 56.3 49.2 0.0647 0.0 30.0
Pre6 37.5 42.8 0.0161 30.0 37.5
Pre4 26.9 39.7 0.0633 37.5 20.0
Precise® average 40.3 43.9 22.5 29.2
Xac8 10.7 3.9 0.0126 91.7 100.0
Xac6 8.4 2.8 0.0059 100.0 100.0
Xact® average 9.6 3.3 95.8 100.0
Fig. 3 Artificial lumen
narrowing. Bars represent
ALN values for CE-MRA
(dark gray bars) and 3D-TOF
(light gray bars) for each stent
in the study. Note: ALN was
0 for the Acc8, Acc6, and Pre8
stents
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reasonable to include the Precise® stent in future in vivo
The Wallstent® is cobalt alloy based and has a closed cell
design. Interestingly, while the larger diameters of this stent
offeredacceptableimage qualitywithCE-MRA,the results of
the4-mmWallstent®andthe3D-TOFimagesofallsizeswere
less favorable. It remains debatable whether this is related to
the stent’s geometry (closed cell design with relatively small
cell size) or its cobalt alloy material. While previous
investigations have shown ALN values as high as 100% for
the Wallstent® [4], in this study, it appears that the
Wallstent® may be suitable for imaging with CE-MRA.
The reason for this discrepancy may be attributed to a
number of factors, including the differences in used
“background tissue” (ultrasound gel vs. normal saline), the
presence of intravascular flow, or the use of a carotid surface
coil. In conclusion, while the previously seen difficulties in
imaging the Wallstent® [4, 5] were also encountered in this
study, it is possible that the use of surface coils in an in vivo
setting may lead to clinically useful results with this stent, at
least for the detection of significant restenosis (>70%).
The other closed cell stent in this study, the Xact®, showed
an almost complete in-stent signal loss (corresponding to
ALN values of up to 100%). This confirms the problematic
MR characteristics of this stent seen in a previous study with
CE-MRA [4]. Although the Xact® stent is made of nitinol, a
material commonly associated with favorable MR imaging
characteristics [4, 15, 16], the lumen of the Xact® was not
readily visible in this study. This supports the hypothesis that
stent geometry and strut architecture may indeed be at least
equally important as stent material in terms of the resulting
image quality. However, the influence of the complex stent
geometry on stent-related artifacts is difficult to predict at
best. Thus, development of stent-specific guidelines for CAS
follow-up imaging may be a beneficial approach to
overcome this problem. For the development of standard
imaging guidelines, different MRA sequence types need to
be compared to other available imaging modalities, such as
CTA and DSA. For follow-up imaging, MRA has the
advantage of included parenchymal stroke imaging. Both
CTA and MRA offer information on the bilateral carotid
bifurcations, whereas DSA is typically performed on the
affected side only. Disadvantages of MRA include relatively
high cost as well as limited availability especially of high-
field scanners and surface coils.
In vivo studies should be performed to overcome the
limitations of the present study: Use of silicone tubes
produces artifacts limiting lumen visibility. The straight
vessel geometry used probably results in flow patterns
differing from in vivo conditions, and artifact patterns may
change when imaging flexed or partially rotated stents in
tortuous vessels. Stent orientation relative to B0 may change
under in vivo conditions and was not assessed in this study
(all stents were oriented in parallel to B0). Furthermore,
processes such as intimal stent overgrowth may significant-
ly alter stent appearance and must therefore be taken into
account [2]. Finally, the objective approach to image
analysis used in this study is helpful to accurately compare
different modalities or sequence types but is of limited
importance in clinical practice. Future studies should also
include evaluation of stenosed vessel segments, which may
prove especially challenging for the 3D-TOF technique due
to stenosis-related turbulence and the possibility of overes-
timation of stenosis with 3D-TOF.
Conclusion
Our results show that 3D-TOF is a viable alternative to CE-
MRA for depicting the in-stent lumen in certain carotid artery
stents. While both sequence types were limited by stent-
related artifacts, 3D-TOF is non-invasive and offers good
image quality with the use of specialized carotid surface coils.
3D-TOF may be particularly useful in situations where use of
contrast media may be harmful, such as concomitant renal or
thyroid disease. For the Zilver®, Acculink®, and Precise®
stents, 3D-TOF provided relative in-stent signal intensities
comparable to CE-MRA. For these stents, further evaluation
of 3D-TOF in an in vivo setting appears to be particularly
promising. For the Wallstent®, both sequence types showed
significant stent-related artifacts. For stent diameters ≥6m m ,
CE-MRA offered acceptable RIS and ALN values with this
stent and shouldbeinvestigatedinvivo.The Xact® stent gave
strong artifacts with both sequence types and seems not well
suited for MR imaging. Thus, stent-specific protocols for
follow-up imaging after CAS may be a reasonable option.
Specifically,invivoexaminations shouldcarefullyinvestigate
the reliability and diagnostic quality of 3D-TOF as compared
to CE-MRA and other modalities in light of the results
presented here.
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